FDA Clearance Tracker · P860004-S066
SYNCHROMED IMPLANTABLE INFUSION SYSTEM FOR THE INTRATHECAL ADMINISTRATION OF PRIALT (ZICONOTIDE)
Last checked: Nov 20, 2026Latest source record: Feb 14, 2005 (this decision)Source: openFDAMethods & limitations
Decided
Feb 14, 2005
Approved
Time to decision
24 days
Received Jan 21, 2005. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P860004-S066
- Device name
- SYNCHROMED IMPLANTABLE INFUSION SYSTEM FOR THE INTRATHECAL ADMINISTRATION OF PRIALT (ZICONOTIDE)
- Applicant
- Medtronic, Inc.
- Applicant location
- Minneapolis, MN
- Received
- Jan 21, 2005
- Decided
- Feb 14, 2005
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P860004
Device type
- Device class
- Class III
- Specialty
- Hospital Medicine & Nursing
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE INTRATHECAL ADMINISTRATION OF PRIALT (ZICONOTIDE). THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME SYNCHROMED IMPLANTABLE INFUSION SYSTEM AND IS INDICATED FOR THE CHRONIC INTRATHECAL INFUSION OF PRESERVATIVE-FREE ZICONOTIDE STERILE SOLUTION FOR THE MANAGEMENT OF SEVERE, CHRONIC PAIN.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.